Nicole A. Shonka, M.D., and Mark R. Gilbert, M.D.
Dr Shonka is a Fellow and Dr. Gilbert is the Deputy Chair and Professor, the Department of Neuro-Oncology, the University of Texas M.D. Anderson Cancer Center, Houston, TX.
Within the past 12 months, Dr. Shonka reports no commercial conflicts of interest, while Dr. Gilbert has received grant/research support from Genentech and Schering-Plough, and been a consultant to Genentech, Pfizer and Schering-Plough.
Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.
Estimated course time: 1 hour(s).
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®, you should be able to:
Highlight pathways important in gliomagenesis
Discuss the current use of molecularly targeted agents for gliomas, as well as efficacy and adverse effects of treatment
Discuss the ongoing research using targeted agents in the treatment of gliomas.
